
Shares of cancer testing services company NeoGenomics NEO.O fall ~15% to $12.2 in morning trade
NEO posts Q4 revenue of $172 million, missing analysts' estimates of $173.2 million, according to data compiled by LSEG
Company reports adj. Q4 profit of 4 cents/shr, compared to analysts' estimates of 3 cents/shr
Company forecasts net loss of $85 million to $76 million for 2025
NEO also forecasts 2025 revenue in the range of $735 million to $745 million
Stock down 3.2% over the past 12 months